Wall Street analysts expect that Teligent, Inc. (NASDAQ:TLGT) will report sales of $16.92 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Teligent’s earnings, with the highest sales estimate coming in at $23.30 million and the lowest estimate coming in at $13.70 million. Teligent reported sales of $17.94 million in the same quarter last year, which suggests a negative year over year growth rate of 5.7%. The business is scheduled to report its next quarterly earnings results on Tuesday, March 6th.

According to Zacks, analysts expect that Teligent will report full year sales of $16.92 million for the current year. For the next financial year, analysts expect that the business will post sales of $97.95 million per share, with estimates ranging from $84.65 million to $116.80 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Teligent.

Teligent (NASDAQ:TLGT) last posted its quarterly earnings data on Monday, November 6th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.07). Teligent had a negative return on equity of 6.38% and a negative net margin of 16.95%. The company had revenue of $13.65 million for the quarter, compared to analysts’ expectations of $19.12 million. During the same period in the prior year, the company posted $0.01 EPS. The firm’s revenue was down 15.5% compared to the same quarter last year.

Several equities analysts recently weighed in on TLGT shares. Zacks Investment Research lowered shares of Teligent from a “hold” rating to a “strong sell” rating in a report on Saturday. Deutsche Bank AG reaffirmed a “hold” rating and issued a $9.00 price target (up from $8.00) on shares of Teligent in a research note on Monday, July 17th. TheStreet downgraded shares of Teligent from a “c-” rating to a “d+” rating in a report on Wednesday, November 1st. Canaccord Genuity initiated coverage on shares of Teligent in a report on Monday, July 31st. They set a “buy” rating and a $11.00 price target on the stock. Finally, ValuEngine lowered shares of Teligent from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $7.33.

Teligent (TLGT) opened at $3.48 on Tuesday. Teligent has a 12 month low of $2.82 and a 12 month high of $9.54. The company has a debt-to-equity ratio of 1.99, a quick ratio of 3.71 and a current ratio of 4.37.

ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/11/14/16-92-million-in-sales-expected-for-teligent-inc-tlgt-this-quarter.html.

Institutional investors and hedge funds have recently modified their holdings of the stock. Parkwood LLC bought a new stake in shares of Teligent in the second quarter valued at about $112,000. UBS Asset Management Americas Inc. acquired a new position in Teligent during the first quarter worth about $170,000. Voya Investment Management LLC increased its stake in shares of Teligent by 16.1% in the second quarter. Voya Investment Management LLC now owns 23,342 shares of the company’s stock valued at $214,000 after buying an additional 3,234 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Teligent in the first quarter valued at approximately $198,000. Finally, American International Group Inc. increased its stake in shares of Teligent by 7.1% in the first quarter. American International Group Inc. now owns 25,488 shares of the company’s stock valued at $199,000 after buying an additional 1,680 shares during the period. Institutional investors and hedge funds own 65.85% of the company’s stock.

Teligent Company Profile

Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.

Get a free copy of the Zacks research report on Teligent (TLGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.